Cardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg (C.P.d.C.G., Y.D.).
Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands (B.S., E.L.R., S.H.).
Circulation. 2020 Jan 28;141(4):313-328. doi: 10.1161/CIRCULATIONAHA.119.042474. Epub 2020 Jan 27.
Cardiovascular disease is an enormous socioeconomic burden worldwide and remains a leading cause of mortality and disability despite significant efforts to improve treatments and personalize healthcare. Heart failure is the main manifestation of cardiovascular disease and has reached epidemic proportions. Heart failure follows a loss of cardiac homeostasis, which relies on a tight regulation of gene expression. This regulation is under the control of multiple types of RNA molecules, some encoding proteins (the so-called messenger RNAs) and others lacking protein-coding potential, named noncoding RNAs. In this review article, we aim to revisit the notion of regulatory RNA, which has been thus far mainly confined to noncoding RNA. Regulatory RNA, which we propose to abbreviate as regRNA, can include both protein-coding RNAs and noncoding RNAs, as long as they contribute, directly or indirectly, to the regulation of gene expression. We will address the regulation and functional role of messenger RNAs, microRNAs, long noncoding RNAs, and circular RNAs (ie, regRNAs) in heart failure. We will debate the utility of regRNAs to diagnose, prognosticate, and treat heart failure, and we will provide directions for future work.
心血管疾病是全球范围内巨大的社会经济负担，尽管在改善治疗方法和实现医疗个体化方面做出了巨大努力，但它仍然是死亡和残疾的主要原因。心力衰竭是心血管疾病的主要表现形式，其发病率已达到流行程度。心力衰竭是心脏内稳态失衡的结果，而心脏内稳态依赖于基因表达的紧密调控。这种调控受多种类型的 RNA 分子控制，其中一些编码蛋白质（所谓的信使 RNA），而另一些缺乏蛋白质编码能力，被称为非编码 RNA。在这篇综述文章中，我们旨在重新审视调控 RNA 的概念，迄今为止，该概念主要局限于非编码 RNA。我们提议将调控 RNA 简称为 regRNA，它可以包括编码蛋白质的 RNA 和非编码 RNA，只要它们直接或间接地有助于基因表达的调控。我们将讨论信使 RNA、microRNA、长非编码 RNA 和环状 RNA（即 regRNA）在心力衰竭中的调控和功能作用。我们将讨论 regRNA 在心力衰竭的诊断、预后和治疗中的应用，并为未来的工作提供方向。
